Philip D Leming
Overview
Explore the profile of Philip D Leming including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
7954
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kashani-Sabet M, Leachman S, Stein J, Arbiser J, Berry E, Celebi J, et al.
JAMA Dermatol
. 2023 Mar;
159(5):545-553.
PMID: 36920356
Importance: Therapy for advanced melanoma has transformed during the past decade, but early detection and prognostic assessment of cutaneous melanoma (CM) remain paramount goals. Best practices for screening and use...
2.
Topalian S, Sznol M, Mcdermott D, Kluger H, Carvajal R, Sharfman W, et al.
J Clin Oncol
. 2023 Feb;
41(5):943-954.
PMID: 36750016
Purpose: Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. PD-1 blockade can mediate...
3.
Grossman D, Okwundu N, Bartlett E, Marchetti M, Othus M, Coit D, et al.
JAMA Dermatol
. 2020 Jul;
156(9):1004-1011.
PMID: 32725204
Importance: Use of prognostic gene expression profile (GEP) testing in cutaneous melanoma (CM) is rising despite a lack of endorsement as standard of care. Objective: To develop guidelines within the...
4.
Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D, et al.
JAMA Oncol
. 2019 Jul;
5(10):1411-1420.
PMID: 31343665
Importance: Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is approved by the US Food and Drug Administration for treating advanced melanoma, renal cell carcinoma (RCC), non-small cell...
5.
Johnson M, Leachman S, Aspinwall L, Cranmer L, Curiel-Lewandrowski C, Sondak V, et al.
Melanoma Manag
. 2017 Aug;
4(1):13-37.
PMID: 28758010
Melanoma is usually apparent on the skin and readily detected by trained medical providers using a routine total body skin examination, yet this malignancy is responsible for the majority of...
6.
Topalian S, Sznol M, Mcdermott D, Kluger H, Carvajal R, Sharfman W, et al.
J Clin Oncol
. 2014 Mar;
32(10):1020-30.
PMID: 24590637
Purpose: Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. PD-1 blockade can mediate...
7.
Slingluff Jr C, Lee S, Zhao F, Chianese-Bullock K, Olson W, Butterfield L, et al.
Clin Cancer Res
. 2013 May;
19(15):4228-38.
PMID: 23653149
Purpose: This multicenter randomized trial was designed to evaluate whether melanoma helper peptides augment cytotoxic T lymphocyte (CTL) responses to a melanoma vaccine and improve clinical outcome in patients with...
8.
Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D, et al.
N Engl J Med
. 2012 Jun;
366(26):2443-54.
PMID: 22658127
Background: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that...